Dimension Therapeutics, Inc. (DMTX) Stock Price Up -1.2%
Dimension Therapeutics, Inc. (NASDAQ:DMTX)’s share price rose 1.2% during mid-day trading on Tuesday . The company traded as high as $5.90 and last traded at $5.83. Approximately 187,520 shares changed hands during mid-day trading, a decline of 12% from the average daily volume of 212,006 shares. The stock had previously closed at $5.90.
DMTX has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $3.00 price objective on Dimension Therapeutics and gave the stock a “hold” rating in a report on Saturday, June 10th. Canaccord Genuity decreased their price objective on Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, June 28th. Zacks Investment Research lowered Dimension Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Chardan Capital reaffirmed a “hold” rating on shares of Dimension Therapeutics in a research note on Monday, August 14th. Finally, Citigroup Inc. lowered Dimension Therapeutics from a “neutral” rating to a “sell” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. Dimension Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.33.
The stock’s market capitalization is $146.55 million. The stock’s 50-day moving average price is $2.42 and its 200 day moving average price is $1.70.
Dimension Therapeutics (NASDAQ:DMTX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49). Dimension Therapeutics had a negative net margin of 358.21% and a negative return on equity of 98.72%. The firm had revenue of $4.37 million during the quarter. On average, equities research analysts predict that Dimension Therapeutics, Inc. will post ($2.10) earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its position in Dimension Therapeutics by 206.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 54,231 shares during the last quarter. Two Sigma Securities LLC bought a new position in Dimension Therapeutics in the 1st quarter worth approximately $108,000. Finally, Weiss Multi Strategy Advisers LLC raised its position in Dimension Therapeutics by 6.7% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 390,403 shares of the biotechnology company’s stock worth $683,000 after purchasing an additional 24,489 shares during the last quarter. Hedge funds and other institutional investors own 70.75% of the company’s stock.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.